Mersana Therapeutics plummets after cancer drug fails study
27/07/2023 13:52
** Shares of cancer drug developer Mersana Therapeutics
MRSN.O plunge 74.4% to $1 premarket, biggest decliner across
U.S. exchanges
** Co says its drug, upifitamab rilsodotin, failed to meet
the main goal of a trial testing it in some patients with
ovarian cancer
** Will wind down development activities related to the drug
and plans to lay off 50% of its workforce
** Shares down ~33% YTD
(Reporting by Manas Mishra in Bengaluru)
((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))